Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells

British Journal of Pharmacology

Volumn 128, Issue 3, 1999, Pages 613-620

  Gazi, L ^a   Bobirnac, I ^a   Danzeisen, M ^a   Schupbach E ^a   Langenegger, D ^a   Sommer, B ^a   Hoyer, D ^a   Tricklebank, M ^a   Schoeffter, P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

3H spiperone binding; Cyclic AMP inhibition; Dopamine D4 receptor; Expression system; L 745,870; Schizophrenia; U 101958

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; BUTYRIC ACID; CYCLIC AMP; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FORSKOLIN; N (1 BENZYL 4 PIPERIDINYL) N (3 ISOPROPOXY 2 PYRIDINYL) N METHYLAMINE; NEUROLEPTIC AGENT; RACLOPRIDE; SPIPERONE;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR DENSITY;

AMINOPYRIDINES; ANIMALS; BUTYRATES; CHO CELLS; CRICETINAE; CYCLIC AMP; DOPAMINE AGENTS; HUMANS; LIGANDS; PIPERIDINES; PYRIDINES; PYRROLES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECOMBINANT PROTEINS; SPIPERONE;

EID: 0032701195     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702849     Document Type: Article

References (31)

1. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
2. CHEN, C. & OKAYAMA, H. (1987). High efficiency transformation of mammalian tells by plasmid DNA. Mol. Cell. Biol., 7, 2745-2752.
3. COCKETT, M.I., BEBBINGTON, C.R. & YARRANTON, G.T. (1990). High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology. 8, 662-667.
4. 1MF-2 cells: comparison of receptor density and response. Eur. J. Pharmacol., 289, 305-310.
5. 4.4 receptor. Br. J. Pharmacol., 124, 889-896.
6. HARTMAN, D.S. & CIVELLI, O. (1997). Dopamine receptor diversity: Molecular and pharmacological perspectives. In: Progress in Drug Research, Vol. 4, ed. Jucker, E. pp. 173-194. Basel: Birkhäuser.
7. HERMANS, E., CHALLISS, R.A.J. & NAHORSKI, S.R. (1999). Effects of varying the expression level of recombinant human mGlulα receptors on the pharmacological properties of agonists and antagonists. Br. J. Pharmacol., 126, 873-882.
8. KEBABIAN, J.W. & CALNE D.B. (1979). Multiple receptors for dopamine. Nature, 277, 93-96.
9. KENAKIN, T.P. (1997). Efficacy. In: Pharmacological analysis of drug-receptor interaction, ed. Kenakin, T.P. pp. 289-330. Philadelphia-New York: Lippincott-Raven.
10. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry, 54, 567-572.
11. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol., 236, 483-486.
12. 1D receptors expressed in various mammalian cell lines. Br. J. Pharmacol., 123, 1655-1665.
13. 3H]raclopride is increased in schizophrenia. Biol. Psychiatry. 42, 648-654.
14. MEADOR-WOODRUFF, J.H., DAMASK, B.S., WANG, J., HAROUTUNIAN, V., DAVIS, K.L. & WARSON, S.J. (1996). Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsy-chopharmacology, 15, 17-29.
15. 4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci., 15, 2186-2191.
16. 4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J. Pharmacol. Exp. Ther., 282, 181-191.
17. PATEL, S., FREEDMAN, S., CHAPMAN, K.L., EMMS, F., FLETCHER, A.E., KNOWLES, M., MARWOOD, R., MCALLISTER, G., MYERS, J., PATEL, S., CURTIS, N., KULAGOWSKI, J.J., LEESON, P.D., RIDGILL, M., GRAHAM, M., MATHESON, S., RATHBONE, D., WATT, A.P., BRISTOW, L.J., RUPNIAK, N.M.J., BASKIN, E., LYNCH, J.J. & RAGAN, C.I. (1997). Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J. Pharmacol. Exp. Ther., 283, 636-647.
18. 3H]NGD 94-1. J. Pharmacol. Exp. Ther., 282, 1020-1027.
19. 4 receptors in the action and development of antipsychotic agents. Drugs, 51, 7-11.
20. 4 receptors in drug-treated schizophrenia. Eur. J. Pharmacol., 281, R5-R6.
21. 3H]cAMP in cell monolayers, cell suspension, and tissue slices. Methods Enzymol., 195, 22-28.
22. 4 receptor. Eur. J. Pharmacol., 322, 283-286.
23. SEEMAN, P., GUAN, H.-C. & VAN TOL, H.H.M. (1993). Dopamine D4 receptors elevated in schizophrenia. Nature, 365, 441-445.
24. 125I]epidepride. Eur. J. Pharmacol., 286, R3-R5.
25. 4 receptor varies with the affinity of the competing radioligand. Eur. J. Pharmacol. Mol. Pharmacol. Section, 291, 59-66.
26. SHARMA, A., KRAMER, M.L., WICK, P.F., LIU, D., CHARI, S., SHIM, S., TAN, W., OUELLETTE, D., NAGATA, M., DURAND, C.J., KOTB, M. & DETH, R.C. (1999). D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol. Psychiatry, 4, 235-246.
27. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res., 681, 109-116.
28. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614.
29. 4 receptor mediated inhibition of potassium current in neurophysial nerve terminals. J. Pharmacol. Exp. Ther., 284, 542-548.
30. 4 receptor ligands: relation to antipsychotic action. Eur. J. Pharmacol., 351, 273-286.
31. 4-receptor analysis?. Pol. J. Pharmacol., 49, 201-211.